JPH09143063A - Composition suitable for external use - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain the above composition suitable for external use such as a cosmetic or a medicine for external use, capable of sufficiently exhibiting characteristics performances of a specific pharmacodynamically effective agent, by blending an astaxanthin with the pharmacodynamically effective agent. SOLUTION: This composition comprises (A) an astaxanthin and (B) one or two selected from (i) an active oxygen scavenger, (ii) an antioxidant, (iii) a cell activator, (iv) an antiinflammatory agent, (v) an tyrosinase activity inhibitor and (vi) a heat reserving agent. Preferably the component (i) is SOD, mannitol, hydroquinone, etc., the component (ii) is a vitamin A, a vitamin B, etc., their derivatives and their salts, the component (iii) is a deoxyribonucleic acid, its salt, etc., the component (iv) is glycyrrhizic acid, glycyrrhetic acid, etc., the component (v) is cysteine, its derivative and its salt and the component (vi) is a mucopolysaccharide and/or a protein.

Description

Detailed Description of the Invention

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a composition suitable for external use, and more particularly to a composition suitable for external use such as cosmetics and external medicines containing astaxanthins and a specific medicinal agent.

[0002]

2. Description of the Related Art Conventionally, cosmetics such as milky lotions, creams, lotions, packs, dispersions, and detergents, and external medicines such as ointments, creams, and liquids for external use have a predetermined medicinal effect. Medicinal ingredients have been added for this purpose. For example, skin blackening and irritation caused by sunburn,
In order to prevent the phenomena such as spots and freckles caused by pigmentation, calamine and the like, and ascorbic acid, glutathione, colloidal sulfur, hydroquinone, cinnamic aldehyde, etc. are blended, and also rough skin improvement, skin aging prevention, cells In addition to activation, allantoin, aloe extract, carrot extract, shikon extract, placenta extract for the purpose of treatment of wounds after cuts and shave, wounds such as cracks, cracks, sores, hemorrhoids, burns, etc. , Medicinal substances such as bovine blood deproteinization products, fermentation metabolites, etc.

[0003]

However, compositions suitable for external use such as cosmetics and external medicines containing these medicinal ingredients (hereinafter sometimes referred to as "external compositions").
Then, the effect of the medicinal ingredient is not enough, or
In many cases, the desired medicinal effect cannot be obtained due to deterioration in the preparation, and such improvement has been desired.

[0004]

Means for Solving the Problems As a result of intensive studies to improve the effect of a medicinal component of a composition for external use, the present inventors have found that if an astaxanthin and a medicinal agent are combined,
The present inventors have found that the action originally possessed by a medicinal agent is sufficiently exhibited, and completed the present invention.

That is, the present invention provides the following components (A) and (B) (A) astaxanthin (B) active oxygen scavenger, antioxidant, cell activating agent, anti-inflammatory agent, tyrosinase activity inhibitor and moisturizing agent. The present invention provides a composition containing one or more medicinal agents selected from agents.

[0006]

BEST MODE FOR CARRYING OUT THE INVENTION The astaxanthins which are the components (A) of the composition of the present invention have already been effective in preventing antioxidants, anti-inflammatory effects (JP-A-2-49091) and skin aging prevention effects (JP-A-5-155736). ), A whitening effect (Abstracts of the 19th Annual Scientific Meeting of the Japanese Cosmetic Science Society, P. 66, 1994). The astaxanthin may be a chemically synthesized product or a product extracted from a natural product such as krill, salmon, trout, fukuju grass, and red yeast. For example, those prepared as follows are preferably used.

[0007] That is, the krill (Euphausi)
a similis GO etc.) is extracted by adding an extraction solvent, and the extract is filtered to obtain an astaxanthin extract, or the extraction solvent is further distilled off from the extract, and if necessary, hydrogenation or hydrolysis may be performed. It is possible to use purified astaxanthins which have been subjected to deodorization and purification using a means such as molecular distillation or column chromatography or high performance liquid chromatography (HPLC) after performing a chemical reaction.

As the extraction solvent, an organic solvent such as acetone, ether, chloroform and alcohol (ethanol, methanol, etc.) can be used, or a mixed solution of these can be used. Alternatively, carbon dioxide in a supercritical state may be used.

The astaxanthins in the present invention include both astaxanthin and its derivatives. Astaxanthin has the formula

Embedded image The carotenoid represented by
Examples thereof include astaxanthin esters, for example, amino acid esters such as glycine and alanine, carboxylic acid esters such as acetic acid esters and citric acid esters and salts thereof, inorganic salt esters such as phosphoric acid esters and sulfuric acid esters and salts thereof, glucosides and the like. Glycosides, or highly unsaturated fatty acids such as eicosapentaenoic acid and docosahexaenoic acid, unsaturated fatty acids such as oleic acid and linoleic acid, or fatty acid esters selected from saturated fatty acids such as palmitic acid and stearic acid And the same or different diesters and the like.

The content of astaxanthins in the composition of the present invention is preferably 0.000001 to 5% by weight (hereinafter simply referred to as "%"), more preferably 0.00.
It is 01 to 1%. When the extract is used, the concentration of the extract is not limited as long as the solute content is within the above range. If the content of this astaxanthin is less than 0.0001%, a sufficient effect may not be obtained, and even if it exceeds 5%, the effect is not further increased.

On the other hand, the drug effect of the component (B) of the present invention is selected from active oxygen scavengers, antioxidants, cell activators, anti-inflammatory agents, tyrosinase activity inhibitors and moisturizers. The following are examples of typical medicinal agents.

(Active oxygen scavenger and antioxidant) Examples of the active oxygen scavenger include SOD, mannitol, hydroquinone, bilirubin, cholesterol, tryptophan, histidine, quercetin, quercitrin,
Examples include gallic acid, gallic acid derivatives, plant extracts containing flavonoids such as Ginkgo biloba extract, Gokahi extract, Yashajitsu extract, Zikoppi extract and the like.

Examples of the antioxidant include vitamin A such as vitamin A acetate and vitamin A palmitate.
C and their derivatives, their salts, vitamins B and their derivatives and their salts, magnesium L-ascorbyl phosphate, disodium sulfate L-ascorbate, vitamin C dipalmitate, and other vitamin C and derivatives thereof; Their salts, vitamin Ds and their derivatives, their salts, vitamin E such as vitamin E acetate and its derivatives and their salts, glutathione and its derivatives and their salts, B
Examples include HT and BHA.

[0014] Among the above active oxygen removing agents and antioxidants,
Especially preferred are mannitol and vitamin C.
And derivatives thereof and salts thereof, vitamin E and derivatives thereof and salts thereof.

(Cell activating agent) Examples of the cell activating agent include deoxyribonucleic acid and salts thereof, adenylic acid derivatives such as adenosine triphosphate and adenosine monophosphate and salts thereof, ribonucleic acid and salts thereof, and guanine. , Xanthine and their derivatives and their salts, and other nucleic acid-related substances; serum-derived protein extracts, spleen extracts, placenta extracts, chicken cob extracts, royal jelly and other animal-derived extracts; yeast extracts, lactic acid extract , Bifidobacteria extract,
Extracts derived from microorganisms such as Ganoderma lucidum extract; extracts derived from plants such as carrot extract, assembly extract, rosemary extract, psyllium extract, garlic extract, hinokitiol, cepharanthin; α- or γ-linolein Acid, eicosapentaenoic acid and derivatives thereof, succinic acid and derivatives thereof and salts thereof, estradiol and derivatives thereof and salts thereof, lactic acid, glycolic acid, citric acid, malic acid, α-hydroxy acids such as salicylic acid and their Examples thereof include derivatives and salts thereof.

Of these cell activators, particularly preferred are deoxyribonucleic acid and its salts, adenosine triphosphate and its salts, serum deproteinized extract, placenta extract,
Examples include yeast extract, carrot extract, succinic acid and its derivatives, and salts thereof.

(Anti-inflammatory agent) As an anti-inflammatory agent,
Glycyrrhizic acid, glycyrrhetinic acid, mefenamic acid,
Phenylbutazone, indomethacin, ibuprofen,
Ketoprofen, allantoin, guaiazulene and their derivatives and salts thereof, ε-aminocaproic acid, zinc oxide, diclofenac sodium, aloe extract, salvia extract, arnica extract, chamomile extract, birch extract, Hypericum perforatum extract, eucalyptus Examples thereof include extracts and mukuroji extracts.

Of these anti-inflammatory agents, particularly preferred are glycyrrhizic acid, glycyrrhetinic acid, guaiazulene and their derivatives, and their salts, ε-aminocaproic acid, aloe extract and chamomile extract.

(Tyrosinase activity inhibitor) Examples of the tyrosinase activity inhibitor include cysteine and its derivatives (for example, N, N'-diacetylcystine dimethyl) and salts thereof, Sempukuka extract, Caiketo extract, Sunpen's extract, Sophoraceae extract. Substance, a Japanese laurel extract, an Ibukittoranoo extract, a Clara extract, a hawthorn extract, a white lily extract, a hop extract, a Neubara extract, a Yokuinin extract, etc. are mentioned.

(Humectant) As the moisturizer, mucopolysaccharide and / or protein, which is a constituent of the skin and has been conventionally blended in cosmetics, can be used.

Among them, examples of the mucopolysaccharide include hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin and keratan sulfate, and salts thereof, and hyaluronic acid, chondroitin sulfate and salts thereof are preferably used. be able to.

Examples of the protein include collagen, elastin, keratin, their derivatives and salts thereof, and collagen is particularly preferable. The origin of each of these components is not particularly limited, and may be any of animal origin, microorganism origin, and synthetic products. There are no particular restrictions on the extraction method and purification method for natural sources.

The amount of the above-mentioned component (B), which is a drug, in the composition of the present invention varies depending on the type of drug,
The range shown below is preferable.

That is, the active oxygen scavenger is generally contained in the composition in an amount of 0.0001 to 5%, preferably 0.000.
1 to 3% is blended. Compounding amount of active oxygen remover is 0.0
If it is less than 0001%, a sufficient effect may not be obtained, and if it exceeds 5%, the effect may not be further increased, and adversely affect the formulation. . These active oxygen scavengers can be used alone or in combination of two or more.

An antioxidant is also generally added to the composition in an amount of 0.0001 to 5%, preferably 0.001 to 3%. If the compounding amount of the antioxidant is larger or smaller than the above range, it is not preferable for the same reason as described above for the active oxygen scavenger. These antioxidants can also be used alone or in combination of two or more.

From the standpoint of stability over time, the cell activating agent is preferably incorporated in the composition in an amount of 0.001 to 5%, more preferably 0.01 to 3%, and one or more of them may be used in combination.

The anti-inflammatory agent is generally present in the composition at 0.0.
It is 001 to 5%, preferably 0.01 to 3%. Each of the anti-inflammatory agents can be used alone or in combination of two or more.

Further, the content of the tyrosinase activity inhibitor in the composition is 0.0001 to 10 as a dry solid content.
%, Particularly preferably 0.001 to 5%. If it is less than 0.0001%, a sufficient whitening effect cannot be obtained, and if it exceeds 10%, the effect does not increase.
Further, in some cases, a problem such as coloring of the product may occur, which is not preferable. These may be used alone or in combination of two or more.

Furthermore, mucopolysaccharides and / or moisturizers
Alternatively, the content of protein in the composition of the present invention is generally 0.0001 to 5%, preferably 0.001 to 3%. If the content of these is less than 0.0001%, a sufficient effect may not be obtained, and even if the content exceeds 5%, the effect is not further increased.
These mucopolysaccharides and proteins can be used alone or in combination of two or more.

The composition of the present invention is prepared by blending the essential components (A) and (B) with various forms of bases known as conventional compositions for external use according to a conventional method. You can

The form of the composition is not particularly limited, and examples thereof include emulsions, creams, lotions, packs, dispersions, detergents, makeup cosmetics, cosmetics such as scalp and hair products, and ointments. It can be used as a medicine such as a cream agent or a liquid agent for external use. Activators, ultraviolet absorbers, thickeners, dyes, preservatives, fragrances and the like can be used.

[0032]

EXAMPLES Next, the present invention will be described in more detail with reference to Reference Examples, Test Examples and Examples, but the present invention is not limited thereto.

Reference Example 1 Extraction of Astaxanthins: Dried Krill Shell 10
Acetone (500 ml) was added to 0 g (astaxanthin content 223 mg%), and the mixture was extracted for 1 hour with stirring. Then, the filtrate obtained by suction filtration was concentrated under reduced pressure with an evaporator, and the obtained concentrated liquid was dried under reduced pressure to obtain 15 g of an astaxanthin extract (astaxanthin content 1.3%).

Reference Example 2 Purification of astaxanthins: 10 g of the extract obtained in Reference Example 1 was subjected to column chromatography.
That is, an inner diameter of 3 cm filled with silica gel and a height of 20
The extract was adsorbed on a cm column made of glass, and the impurities were eluted with 500 ml of n-hexane, and then the astaxanthins were eluted with acetone. This eluate was concentrated under reduced pressure with an evaporator and further subjected to steam distillation to obtain 0.8 g of a purified substance of astaxanthin (content of astaxanthin: 14.6%).

Test Example 1 Superoxide removal activity measurement test: The astaxanthins obtained in Reference Example 2 and the active oxygen scavengers shown in Table 1 were used alone or as a mixture to prepare samples, and the superoxide removal activity was determined by the following measurement method. Was measured. That is,
0.05M sodium carbonate buffer (pH 10.2) 2.4
Substrate solution [3.0 mM xanthine (dissolved in 0.05 M sodium carbonate buffer)] in 0.1 ml, 3.0 mM
0.1 ml of EDTA, 0.1 ml of 0.15% (W / V) bovine serum albumin, 0.1 ml of 0.75 mM nitroblu-tetrazolium and 0.1 ml of each test sample were mixed together, and 2
It was left at 5 ° C. for 10 minutes. Then, the enzyme solution [xanthine oxidase solution (purified water approximately 0.04 units / ml
Dilution)] 0.1 ml to start the reaction and
After incubating for 0 minutes, 6 mM CaCl ₂ 0.1
Stop the reaction by adding ml. Then, the absorbance (A) at 560 nm is measured.

The absorbance (B) of the sample to which purified water was added instead of the test sample was used as a control, and 6 was used as the blank of each sample.
After stopping the reaction by adding 0.1 ml of mM CaCl _2, the absorbance (C) of the sample to which 0.1 ml of xanthine oxidase was added was measured, and the superoxide removal rate was calculated from the following formula. Table 1 shows the results.

[0037] A: Absorbance of sample by enzyme reaction B: Absorbance of control enzyme reaction C: Absorbance of sample without enzyme reaction

[0038] (Note) Numbers of astaxanthins, SOD, and Ginkgo biloba in the table represent the weight (μg) in 0.1 ml of each sample. * 1 Manufactured in Reference Example 2. * 2 Sigma; obtained from bovine red blood cells (3.570 units / mg). * 3 50 parts of 50 V / V% ethanol aqueous solution was added to 10 parts of ginkgo leaves, extracted at room temperature for 3 days and then filtered.

As is clear from the results shown in Table 1, the astaxanthins obtained in Reference Example 2 had an SOD-like action by themselves, but when used in combination with SOD or Ginkgo biloba extract, a synergistic action was obtained. It was demonstrated that it was extremely effective in removing active oxygen.

This means that the composition of the present invention in which an astaxanthin and an active oxygen scavenger are used in combination is effective against the production of lipid peroxide, inflammation, darkening and aging due to the production of active oxygen in the skin by ultraviolet rays. Shows that it has an extremely high preventive effect.

Example 1 Emulsion: An emulsion was prepared according to the composition shown in Table 2 and the following production method, and its skin beautifying effect and skin aging preventing effect were examined. Table 3 shows the results.

(Composition) Table 2 ─────────────────────────────────── Comparative product of the present invention Component (%) ───── ───────────── 1 1 2 3 ──────────────────────── ──────────── (1) Squalane 5.0 5.0 5.0 5.0 5.0 (2) Vaseline 2.0 2.0 2.0 2.0 (3) Beeswax 0.0. 5 0.5 0.5 0.5 (4) sorbitan sesqui 0.8 0.8 0.8 0.8 oleate (5) polyoxyethylene 1.2 1.2 1.2 1.2 1.2 oleyl ether (20E.O.) (6) 1,3-Butylene 5.0 5.0 5.0 5.0 5.0 Glycol (7) Astaxanthins ^{* 1} 0.01 0.01 --- (8) dl-α-tocopherol ^{* 2} 0.01-0.01- (9) Ethyl alcohol 5.0 5.0 5.0 5.0 (10) Preservative 0.20 .2 0.2 0.2 (11) Fragrance 0.1 0.1 0.1 0.1 0.1 (12) Xanthan gum 20.0 20.0 20.0 20.0 (2% aqueous solution) (13) Residual water production Residual volume Residual volume Residual volume ─────────────────────────────────── * 1 Reference example 2 * 2 Wako Pure Chemical Industries

(Production Method) A. Components (7), (9) and (13) are mixed by heating and kept at 70 ° C. B. Components (1) to (6), (8) and (10) are heated and mixed at 70 ° C.
To keep. C. The above B was added to the above A and mixed, the component (12) was added to uniformly emulsify, the mixture was cooled to 30 ° C., the component (11) was added,
Mix uniformly to obtain an emulsion.

(Test Method) For each test emulsion,
A panel of 15 women, 26 to 50 years old, was applied twice daily in the morning and night twice for 12 weeks, and then applied an appropriate amount of the test emulsion onto the face. The beautiful skin and anti-aging effect of the application were evaluated according to the following criteria.

Skin beautifying effect: [Evaluation] [Content] Effectiveness The dullness of the skin became inconspicuous. Somewhat effective The dullness of the skin became less noticeable. Ineffective No change from before use.

Skin Aging Preventive Effect: [Evaluation] [Content] Effectiveness The scalp and gloss of the skin were improved. Slightly effective Skin glue, gloss slightly improved. Ineffective No change from before use.

(Result) Table 3 ─────────────────────────────────── Beautiful skin effect Effect skin aging prevention Efficacy Test emulsion ──────────── ───────────── Effective Fair Effective Ineffective Effective Fair Effective Ineffective ────────── ──────────────────────── Product of the present invention 1 11 4 0 10 5 0 ──────────────── ────────────────── Comparative products 1 2 7 6 2 6 7 2 0 6 9 9 1 3 11 3 3 0 2 13 0 4 11 11 ──────── ──────────────────────────

As shown in the results of Table 3, by applying to the skin a composition in which astaxanthins represented by the product 1 of the present invention and an antioxidant are combined, dullness of the skin is suppressed and beautiful skin is obtained. , It was found that the skin's elasticity and gloss were improved, and that skin aging was prevented.

Example 2 Cream: A cream was prepared according to the composition shown in Table 4 and the following production method, and its skin beautifying effect and skin aging preventing effect were examined. Table 5 shows the results.

(Composition) Table 4 ──────────────────────────────────── Comparison of the product of the present invention Component (%) ────── ─────────────── 2 3 4 5 6 7 ───────────────── ─────────────────── (1) Beeswax 6.0 6.0 6.0 6.0 6.0 6.0 6.0 (2) Cetanol 5.0 5. 0 5.0 5.0 5.0 5.0 (3) Reduced lanolin 5.0 5.0 5.0 5.0 5.0 5.0 5.0 (4) Squalane 30.0 30.0 30.0 30 .0 30.0 30.0 (5) Glycerin 4.0 4.0 4.0 4.0 4.0 4.0 4.0 Monostearate (6) Lipophilic monostea 2.0 2.0 2.0 2 .0 2.0 2.0 Glycerine phosphate (7) Polyoxyethylene sorbitan monora 2.0 2.0 2.0 2.0 2.0 2.0 Ter (20 EO) (8) Astaxane 0.01 0.01 0.01 --- Tinines ^{* 1} (9) Ascorbic acid phosphoric acid ester 1.0 --- 1.0 --- Magnesium ^{* 2} (10) Mannitol ^{* 3} − 1.0 − − 1.0 − (11) Preservative 0.2 0.2 0.2 0.2 0.2 0.2 (12) Fragrance 0.05 0.05 0.05 0.05 0.05 0.05 0.05 (13) Purified water Remaining amount Remaining amount Remaining amount Remaining amount Remaining amount ──────────────────────── ───────────── * 1 Manufactured in Reference Example 2 * 2 Nikko Chemicals * 3 Wako Pure Chemical Industries

(Production Method) A. Components (1) to (8), (11) and (12) are mixed and heated to 7
Keep at 0 ° C. B. Heat component (13) to 70 ° C. C. B was added to A, mixed, cooled, (9) and (10) were added, and the mixture was mixed uniformly to obtain a cream. (Test method) Same as Example 1 (evaluation standard) 〃

(Results) Table 5 ──────────────────────────────────── Beautiful skin Effectiveness Skin Anti-aging effect Test cream ──────────── ──────────── Effective slightly effective Not effective Effective slightly effective Not effective ───────── ─────────────────────────── Inventive product 2 11 4 0 10 3 2 3 8 3 5 5 2 11 3 1 1 ─────── ──────────────────────────── Comparative product 4 3 5 7 7 1 6 6 8 5 5 5 5 5 2 2 6 7 6 6 1 5 9 3 6 6 7 4 11 0 5 10 ─────────────────────────────────────

As shown in the results of Table 5, application of a composition comprising astaxanthins represented by the products 2 and 3 of the present invention and an antioxidant or an active oxygen scavenger to the skin gives dull skin and the like. It became clear that the skin was pressed down and the skin became beautiful, and that the skin's suppleness and gloss were improved and skin aging was prevented.

Example 3 Cosmetic water: (treatment) Amount (%) (1) Glycerin 5.0 (2) 1,3-Butylene glycol 6.5 (3) Polyoxyethylene sorbitan 1.2 Monolauric acid ester (20E.O.) (4) Ethyl alcohol 8.0 (5) Astaxanthins ^{* 1} 0.0005 (6) SOD ^{* 2} 0.5 (7) Preservative Suitable amount (8) Flavor suitable Amount (9) Residual amount of purified water * 1 Produced in Reference Example 2. * 2 Sigma; obtained from human red blood cells (5.230 units / mg)

(Production Method) A. Components (3), (4), (5), (7) and (8) are mixed and dissolved. B. Components (1), (2), (6) and (9) are mixed and dissolved. C. A and B were mixed and homogenized to obtain a lotion.

Example 4 Pack: (Method) Amount (%) (1) Polyvinyl alcohol 20.0 (2) Ethyl alcohol 20.0 (3) Glycerin 5.0 (4) Kaolin 6. 0 (5) Astaxanthins ^{* 1} 0.05 (6) Ginkgo biloba extract ^{* 2} 0.2 (7) Preservative 0.2 (8) Fragrance 0.1 (9) Residue of purified water * 1 Reference Manufactured in Example 2 * 2 50 parts of 50V / V% ethanol aqueous solution was added to 10 parts of ginkgo leaves, extracted at room temperature for 3 days, and then filtered.

(Production Method) A. Components (1), (3), (4) and (9) are mixed, heated to 70 ° C. and stirred. B. Mix components (2), (5), (7) and (8). C. Add the above B to the above A, mix and cool (6)
Were uniformly dispersed to obtain a pack.

Example 5 Washing agent: (Method) Amount (%) (1) Stearic acid 10.0 (2) Palmitic acid 8.0 (3) Myristic acid 12.0 (4) Lauric acid 4.0 (5) Oleyl alcohol 1.5 (6) Purified lanolin 1.0 (7) Fragrance 0.1 (8) Preservative 0.2 (9) Glycerin 18.0 (10) Potassium hydroxide 6 .0 (11) Astaxanthin ^{* 1} 0.5 (12) Acetic acid-dl-α-0.05 Tocopherol ^{* 2} (13) Residual amount of purified water * 1 Manufactured in Reference Example 2 * 2 Sigma

(Production Method) A. Components (9), (10) and (13) are mixed and heated to 70 ° C. B. Ingredients (1) to (6), (8), (11) and (12) are mixed to obtain 70
Heat to ° C. C. The above B was added to the above A, kept at 70 ° C. for a while, cooled to 50 ° C. after completion of the saponification reaction, the component (7) was added and cooled to obtain a cleaning agent.

Example 6 Lipstick: Lipstick was prepared according to the following formulation and production method. (Direction) Amount (%) (1) Astaxanthin ^{* 1} 0.02 (2) Ergocalciferol ^{* 2} 0.02 (3) Red No. 202 0.2 (4) Candelilla wax 9.0 ( 5) Solid paraffin 8.0 (6) Beeswax 5.0 (7) Carnauba wax 5.0 (8) Lanolin 11.0 (9) Isopropyl myristate ester 10.0 (10) Residual amount of refined castor oil * 1 Reference example Manufactured in 2. * 2 Wako Pure Chemical Industries

(Production Method) A. Components (4) to (10) are heated and dissolved, and then kneaded with three rollers. B. After adding the components (1) to (3), use the three rollers again to add 2
Knead. C. Cool and mold to obtain lipstick.

Test Example 2 Wound healing test: Male Wistar rats aged 8 weeks were used as an experiment in groups of 10 rats. After shaving the back of the rat, under anesthesia, two left and right back skins were incised over a length of 4 cm so as to be symmetrical to the midline. One was used as a drug application site and the other was used as a control site. Immediately after the incision, both incised sites were sutured and wiped with ethanol for disinfection. Among the sutured portions, any one of the present invention products 4 to 6 and comparative products 8 to 11 (dissolved in physiological saline) shown in Table 6 was applied to the drug application site, and physiological saline was applied to the control site. 0.1 ml was applied twice a day for 1 week.

After one week, the dorsal skin was peeled off to prepare a strip-shaped section centering on the incision, and the tensile strength of the skin section was measured using a rheometer NRM-2002J (Fudo Industry Co., Ltd.). The wound healing rate was calculated from the obtained measured value by the following formula. The results are shown in Table 6.

[0064]

[0065]

* 1 Produced in Reference Example 2. * 2 Wako Pure Chemical Industries * 3 Sansho Pharmaceutical * 4 Nikko Chemicals

As shown in the results of Table 6, when the composition of the present invention in which astaxanthins and a cell activating agent such as ATP, placenta extract and yeast extract are combined is applied to the skin,
It was revealed that the wound healing rate was high and that skin trauma, cracks, cracks, sores, hemorrhoids, burns, etc. could be effectively improved and treated.

Example 7 Cream: A cream was prepared by the composition shown in Table 7 and the following production method, and its skin beautifying effect and skin aging preventing effect were examined. Table 8 shows the results.

(Composition) * 1 Manufactured in Reference Example 2 * 2 Sansho Pharmaceutical * 3 Pentafarm

(Production Method) A. Components (1) to (8), (11) and (12) are mixed and heated to 7
Keep at 0 ° C. B. Mix components (9), (10) and (13) and heat to 70
Keep at ° C. C. B was added to A and mixed, and cooled to 30 ° C. to obtain a cream.

(Test Method) For each test cream product, 15 women aged 28 to 54 were used as a panel, and an appropriate amount of the test cream was applied to the face after washing the face for 12 weeks twice a day every morning and night. . The effect of applying beautiful skin and the effect of preventing skin aging were evaluated according to the same criteria as in Example 1.
Table 8 shows the results.

(Result)

As shown in the above results, the composition of the present invention containing astaxanthins represented by the products 7 and 8 of the present invention and the cell activator was applied to the skin to give a dull skin. It became clear that the skin was pressed down and the skin became beautiful, and that the skin's suppleness and gloss were improved and skin aging was prevented.

Example 8 Modified cosmetic water: (Method) Compounding amount (%) (1) Polyoxyethylene (60 EO) hydrogenated castor oil 1.0 (2) Ethanol 15.0 (3) Preservative 0.1 (4) Hinokitiol 0.01 (5) Perfume proper amount (6) Astaxanthin ^* 0.01 (7) Citric acid 0.1 (8) Sodium citrate 0.3 (9) 1,3-butylene Glycol 4.0 (10) Residual amount of purified water * Produced in Reference Example 2.

(Production Method) A. Components (1) to (6) are heated and mixed to dissolve. B. Components (7) to (10) are heated and mixed to dissolve. C. A and B were mixed to obtain a lotion.

Example 9 Emulsion: (Method) Blending amount (%) (1) Polyoxyethylene (10 EO) 1.0 Sorbitan monostearate (2) Polyoxyethylene (60 EO) 0.5 Sorbit tetraoleate (3) Glyceryl monostearate 1.0 (4) Stearic acid 0.5 (5) Behenyl alcohol 0.5 (6) Squalane 8.0 (7) Eicosapentaenoic acid 5.0 (8) ) Antiseptic 0.1 (9) Astaxanthin ^* 0.1 (10) Carboxyvinyl polymer 0.1 (11) Sodium hydroxide 0.05 (12) Ethyl alcohol 5.0 (13) Residual amount of purified water (14) Perfume proper amount * The one produced in Reference Example 2.

(Production Method) A. Components (10) to (13) are mixed by heating and kept at 70 ° C. B. Components (1) to (9) are mixed by heating and kept at 70 ° C. C. Add A to B, mix and emulsify uniformly. After cooling D.C., (14) was added and uniformly mixed to obtain an emulsion.

Example 10 Ointment: (Method) Blending amount (%) (1) Stearic acid 18.0 (2) Cetanol 4.0 (3) Triethanolamine 2.0 (4) Glycerin 5.0 (5) Astaxanthins ^{* 1} 1.0 (6) Lactic acid ^{* 2} 1.0 (7) Residual amount of purified water * 1 Manufactured in Reference Example 2 * 2 Wako Pure Chemical Industries

(Manufacturing method) A. A part of the components (3), (4) and (7) is heated and mixed, and the mixture is heated to 75 ° C.
To keep. B. Ingredients (1), (2) and (5) are mixed by heating and kept at 75 ° C. C. Add A slowly to B. While cooling DC, add (6) dissolved in the remainder of (7),
An ointment was obtained.

Test Example 3 Anti-inflammatory effect and whitening effect: A lotion containing the agents shown in Table 9 and 15% (v / v) of ethanol and the remainder being purified water was prepared and applied to the back of a colored guinea pig. The effect of sunburn on inflammation and pigmentation was examined. Table 10 shows the results.

(Test method) Colored guinea pigs (10 in each group)
) Were shaved and irradiated with ultraviolet light under anesthesia. Ultraviolet irradiation is performed by using FL20S / BLB lamp manufactured by Toshiba Corporation and F
Three L20S / E30 lamps were simultaneously irradiated, and the amount of ultraviolet rays was 4.8 × 10 ⁴ erg / cm ² . 0.2 ml of the sample was rubbed well into the four places on the back of the guinea pig 24 hours before, immediately after the irradiation, and 12 hours after the irradiation, and 24 hours after the irradiation. The application site was thoroughly washed with warm water before irradiation with ultraviolet rays. The degree of inflammation was observed 24 hours after irradiation and the degree of pigmentation 7 days later.

[0082] * 1 Manufactured in Reference Example 2. * 2 Maruzen Pharmaceuticals * 3 Wako Pure Chemicals * 4 Maruzen Pharmaceuticals

(Evaluation Criteria) Evaluation Criteria for Inflammation (Anti-Inflammatory Effect) 0: No inflammation is observed at all 1: Very slight inflammation is observed 2: Inflammation is observed but the boundary with the non-irradiated site is unclear 3 : Inflammation was observed and the boundary with the non-irradiated area was clear

Evaluation criteria for pigmentation (whitening effect) 0: No pigmentation is observed at all 1: Very slight pigmentation is observed 2: Pigmentation is observed, but the boundary with the non-irradiated site is unclear 3: Pigmentation is observed and the boundary with the non-irradiated area is clear

According to the above evaluation criteria, each score is 1
Count how many out of 10 guinea pigs are below the score,
It judged according to the following judgment criteria.

(Judgment Criteria) [Judgment] [Content] Out of 10 animals, the number of guinea pigs having a score of 1 or less is 8 or more. Effectiveness Out of 10 animals, the number of guinea pigs with a score of 1 or less is 6 or more. Somewhat effective out of 10 guinea pigs with a score of 1 or less are 4 or more. Ineffective Out of 10 animals, the number of guinea pigs with a score of 1 or less is 3 or less.

[0087]

From the results shown in Table 10, the composition of the present invention containing an astaxanthin and an anti-inflammatory agent such as dipotassium glycyrrhizinate, guaiazulene, and an aloe extract can be applied to the skin to cause skin inflammation and pigmentation. It became clear to suppress.

Example 11 Cream: A cream was prepared by the following formulation and the following production method. (Method) Compounding amount (%) (1) Polyoxyethylene monostearate (40E.O.) 2.0 (2) Glyceryl monostearate (self-emulsifying type) 5.0 (3) Stearic acid 5.0 (4) Behenyl alcohol 0.5 (5) Squalane 15.0 (6) Cetyl isooctanoate 5.0 (7) Butylparaben 0.1 (8) Methylparaben 0.1 (9) 1,3-Butylene glycol 5.0 (10) Dipotassium glycyrrhizinate ^{* 1} 0.2 (11) Astaxanthins ^{* 2} 0.5 (12) Purified water balance (13) Fragrance suitable amount * 1 Maruzen Pharmaceuticals * 2 Produced in Reference Example 2 thing

(Production Method) A. Components (1) to (7) and (11) are heated and dissolved at 70 ° C. B. Components (8) to (10) and (12) are heated and dissolved at 70 ° C. C. Add A to B and emulsify. Ingredient (13) is added to DC and cooled to obtain a cream.

Example 12 Emulsion: An emulsion was prepared by the following formulation and the following production method. (Method) Compounding amount (%) (1) Polyoxyethylene sorbitan 1.0 Monostearate (10 EO) (2) Polyoxyethylene sorbit 0.5 Tetraoleate (60 EO) (3) Glyceryl monostearate 1.0 (4) Stearic acid 0.5 (5) Behenyl alcohol 0.5 (6) Refined avocado oil 4.0 (7) Glyceryl tri-2-ethylhexanoate 4.0 (8) Butylparaben 0.1 (9) ) Astaxanthins ^{* 1} 1.0 (10) Aloe extract ^{* 2} 0.2 (11) Methylparaben 0.1 (12) Carboxyvinyl polymer 0.07 (13) 1,3-Butylene glycol 5.0 (14) Purified water balance (15) Sodium hydroxide 0.025 (16) Purified water 7.5 (17) Fragrance Suitable amount * 1 Produced in Reference Example 2. * 2 Made by Maruzen Pharmaceutical Co., Ltd.

(Production Method) A. Components (1) to (9) are heated and dissolved at 70 ° C. B. Components (10) to (14) are heated and dissolved at 70 ° C. C. Add A to B and emulsify. (15) to (17) are added to DC and cooled to obtain an emulsion.

Example 13 Chemical lotion: A lotion was prepared by the following formulation and the following production method. (Method) Blending amount (%) (1) Polyoxyethylene hydrogenated castor oil (60E.O) 1.0 (2) Perfume proper amount (3) Ethanol 10.0 (4) Methylparaben 0.1 (5) Chamomile Extract ^{* 2} 0.3 (6) Citric acid 0.1 (7) Sodium citrate 0.3 (8) 1,3-Butylene glycol 5.0 (9) Astaxanthins ^{* 1} 0.01 (10) Purified Residual water production volume * 1 Produced in Reference Example 2. * 2 Made by Ichimaru Falcos

(Production Method) A. Components (1) to (4) and (9) are mixed and dissolved. B. Components (5) to (8) and (10) are mixed and dissolved. C. Add B to A and stir to obtain a lotion.

Reference Example 3 Production of plant extract: Sohakuhi (Japanese), Kujin (Clara) (Japanese), Touki (Japanese), hop (flower spike) 1 each
70% (v / v) 100% ethyl alcohol per 0 g
ml was added, and the mixture was extracted at room temperature for 3 days with occasional stirring and filtered to obtain each plant extract.

Test Example 4 Tyrosinase activity inhibition test: Reference Example 2 by the following method
With respect to the 0.5% (W / V) solution of the extract obtained in 1. and the extract obtained in Reference Example 3, the tyrosinase activity inhibition rate of the sample alone or in combination thereof was examined. That is, an enzyme solution [manufactured by Sigma, 28,000 units of tyrosinase 10 mg was added to each sample in 0.1 M phosphate buffer (pH 6.8) 2
Dissolved in 0 ml] 0.1 ml was added, and 0.1 was added.
M phosphate buffer (pH 6.8) was added to make 4.0 ml, and this was incubated at 25 ° C. for 10 minutes.

Then, the substrate solution [L-DOPA (Tokyo Kasei) 198.0, which was previously kept at 25 ° C., was added thereto.
mg dissolved in 100 ml of 0.1 M phosphate buffer (pH 6.8)] 1.0 ml was added and reacted for 10 minutes. After the reaction, the absorbance (OD _s ) at 475 nm was measured. Similarly, the absorbance (OD _HE ) and the absorbance (OD _B ) when the reaction was performed using the enzyme inactivated by heating and when no sample was added were calculated, and the activity inhibition rate of tyrosinase activity was calculated from the following equation. did.

[0098] OD _S : Absorbance of sample OD _B : Absorbance without addition of sample OD _HE : Absorbance when enzyme is inactive Table 11 shows the results.

[0099] * Manufactured in Reference Example 2.

As is clear from Table 11, when the astaxanthins and the tyrosinase activity inhibitor were combined,
Tyrosinase activity inhibitory action is higher than when astaxanthin or tyrosinase activity inhibitor is used alone,
It showed a synergistic whitening effect. Therefore, the composition of the present invention, which is a combination of astaxanthins and a tyrosinase activity inhibitor, by applying this to the skin, exhibits an extremely excellent tyrosinase activity inhibitory action, blackening of the skin due to sunburn etc., stains, Effectively suppress freckles.

Example 14 Emulsion: An emulsion having the composition shown in Table 12 was produced and evaluated for its whitening effect. Table 13 shows the results.

[0102] * 1 Manufactured in Reference Example 2 * 2 Cysteine (manufactured by Wako Pure Chemical Industries, Ltd.) was diluted with water to a concentration of 1.0 mg / ml and used. * 3 Manufactured in Reference Example 3.

<Production Method> A. (6) to (10), (14) and (15) are mixed by heating and kept at 70 ° C. B. (1) to (5), (11) and (12) were mixed by heating and kept at 70 ° C. C. B is added to A and mixed, and (13) is further added to uniformly emulsify and cool to 30 ° C. to obtain an emulsion.

<Whitening Effect Test> For each test emulsion,
A panel of 15 women aged between 25 and 50 was used twice daily in the morning and at night, and after each face wash, the test emulsion was applied to the face in an appropriate amount of 12
By applying over a week, a use test was carried out, and the following criteria were evaluated. Evaluation criteria; Effective: Spots and freckles are not noticeable. Slightly effective: Spots and freckles have become less noticeable. Ineffective: No change.

[0105]

As is apparent from Table 13, 12 and 13 of the products of the present invention in which astaxanthins and tyrosinase activity inhibitors are combined in combination are comparative products 20 containing none of them.
Not only when compared with, but also comparative products 21 to 21 containing astaxanthin or a tyrosinase activity inhibitor alone
Compared with No. 23, the effect of making spots and freckles inconspicuous was excellent and a remarkable whitening effect was exhibited. Therefore, stains, freckles, etc. can be suppressed by applying to the skin the composition of the present invention in which astaxanthins and a tyrosinase activity inhibitor are combined in combination.

Example 15 Modified cosmetic water: <Method> Coordination amount (%) (1) Glycerin 5.0 (2) 1,3-Butylene glycol 6.5 (3) Polyoxyethylene sorbitan 1.2 Monolauric acid ester (20E.O.) (4) Ethyl alcohol 8.0 (5) Astaxanthins ^{* 1} 0.01 (6) Yokuinin extract ^{* 2} (as dry solids) 0.05 (7) Preservative Suitable Quantity (8) Fragrance Suitable quantity (9) Purified water Residual amount * 1 Produced in Reference Example 2. * 2 Made by Maruzen Pharmaceutical Co., Ltd.

<Production Method> A. (3), (4), (5), (7) and (8) are mixed and dissolved. B. (1), (2), (6) and (9) are mixed and dissolved. C. A and B were mixed and homogenized to obtain a lotion.

Example 16 Cream: <Method> Amount (%) (1) Beeswax 6.0 (2) Cetanol 5.0 (3) Reduced Lanolin 5.0 (4) Squalane 30.0 (5) ) Glycerin monostearate 4.0 (6) Lipophilic glyceryl monostearate 2.0 (7) Polyoxyethylene sorbitan 2.0 Monolauric acid ester (20E.O.) (8) Astaxanthin ^{* 1} 1.0 (9) Sophoraceae extract ^{* 2} (as dry solids) 0.2 (10) Preservative 0.3 (11) Perfume 0.05 (12) Purified water balance ^{* 1} Produced in Reference Example 2 * 2 Made by Maruzen Pharmaceutical Co., Ltd.

<Production Method> A. (1) to (8), (10) and (11) are mixed and heated to 70 ° C.
To keep. B. Mix (9) and (12), heat and keep at 70 ° C. C. B was added to A, mixed, and cooled to obtain a cream.

Example 17 Washing agent: <Method> Amount (%) (1) Stearic acid 10.0 (2) Palmitic acid 8.0 (3) Myristic acid 12.0 (4) Lauric acid 4.0 (5) Oleyl alcohol 1.5 (6) Purified lanolin 1.0 (7) Fragrance 0.1 (8) Preservative 0.2 (9) Glycerin 18.0 (10) Potassium hydroxide 6. 0 (11) Astaxanthins ^{* 1} 0.2 (12) Hop extract ^{* 2} 0.01 (13) Residual amount of purified water * 1 Produced in Reference Example 2. * 2 Made by Koei Kogyo Co., Ltd.

<Production Method> A. (9), (10) and (13) are mixed and heated to 70 ° C. B. Mix (1) to (6), (8) and (11) and heat to 70 ° C. C. Add B to A, keep at 70 ° C for a while, cool to 50 ° C after the saponification reaction is completed, add (7) and (12),
Cooled to obtain the cleaning charge.

Example 18 Emulsion: An emulsion was prepared by the composition shown in Table 14 and the following production method, and its rough skin improving effect was examined. The results are shown in Table 15.
Shown in

(Composition) * 1 Manufactured in Reference Example 2. * 2 Made by Nikko Chemicals * 3 Made by Koken

(Production Method) A. Each of the components (6), (8) to (10) and (14) was heated and mixed, and
Keep at 0 ° C. B. The components (1) to (5), (7), (11) and (12) were mixed by heating and kept at 70 ° C. C. The above B was added to the above A and mixed, and the component (13) was added to uniformly emulsify, and the mixture was cooled to 30 ° C. to obtain an emulsion.

(Test Method) For each test emulsion,
A panel of 15 healthy people aged 24 to 45 years was used to photograph the skin condition before inducing experimental rough skin with a microscope camera, and the score was calculated according to the following criteria. Experimental rough skin was treated with ether and acetone (1: 1) on the flexed upper arm.
It was caused by treatment with the mixed solution. After that,
The test milky lotion was applied twice daily in the morning and at night for 7 days, and the skin condition score was obtained 3, 5 and 7 days after the induction of rough skin.

Skin condition score: [Score] [Status] 1 The skin groove of the skin is unclear, and peeling of the keratin is observed. 2 Skin crevices are slightly unclear or strongly unidirectional. 3 Skin sulcus is recognized but shallow or strongly unidirectional. 4 Skin sulcus is recognized or slightly reticulated. 5 Skin crevices are clearly recognized or have a fine mesh.

(Result)

As shown in the results of Table 15, the product of the present invention 1
The composition of the present invention in which the astaxanthins represented by 4 and the mucopolysaccharide are combined, and the composition of the present invention in which the astaxanthins and the proteins represented by the present invention 15 are combined, are applied to the skin to give the skin. It has become clear that the roughness of the can be improved.

Example 19 Cream: A cream was prepared according to the composition shown in Table 16 and the following production method, and its skin beautifying effect was examined. The results are shown in Table 17.
Shown in

(Composition) * 1 Manufactured in Reference Example 2 * 2 Seikagaku Corporation * 3 Ichimaru Falcos

(Production Method) A. Components (1) to (8), (11) and (12) are mixed and heated to 7
Keep at 0 ° C. B. Mix components (9), (10) and (13) and heat to 70 ° C.
To keep. C. B was added to A, mixed, and cooled to obtain a cream.

(Test Method) For each test cream product, 15 women aged 27 to 54 were used as a panel, and an appropriate amount of the test cream was applied to the face twice daily in the morning and at night for 12 weeks. The beautiful skin effect of the application was evaluated according to the following criteria.

(Evaluation standard) Skin beautifying effect: [Evaluation] [Content] Effective The dullness of the skin became inconspicuous. Somewhat effective The dullness of the skin became less noticeable. Ineffective No change from before use.

(Result)

As shown in the results of Table 17, the product of the present invention 1
The composition of the present invention in which astaxanthins represented by 6 and mucopolysaccharides are combined, and the composition of the present invention in which astaxanthins and proteins represented by the present invention 17 are combined, are applied to the skin to give skin. It has been revealed that it is possible to prevent and improve the occurrence of “dullness” and the like, and to make beautiful skin.

Example 20 Chemical lotion: lotion was prepared by the following formulation and the following production method. (Method) Amount (%) (1) Glycerin 5.0 (2) 1,3-Butylene glycol 6.5 (3) Polyoxyethylene sorbitan 1.2 Monolauric acid ester (20E.O.) (4) ) Ethyl alcohol 8.0 (5) Astaxanthins ^{* 1} 0.005 (6) Collagen ^{* 2} 0.5 (7) Preservative Suitable amount (8) Fragrance Suitable amount (9) Purified water residual amount * 1 The one manufactured in Reference Example 2. * 2 Made by Koken

(Production Method) A. Components (3) to (5), (7) and (8) are mixed and dissolved. B. Components (1), (2), (6) and (9) are mixed and dissolved. C. A and B were mixed and homogenized to obtain a lotion.

Example 21 Pack: A pack was prepared according to the following formulation and the following production method. (Process) Amount (%) (1) Polyvinyl alcohol 20.0 (2) Ethyl alcohol 20.0 (3) Glycerin 5.0 (4) Kaolin 6.0 (5) Astaxanthins ^{* 1} 0.5 (6) Sodium hyaluronate ^{* 2} 0.01 (7) Preservative 0.2 (8) Fragrance 0.05 (9) Purified water balance * 1 Produced in Reference Example 2. * 2 Made by Kewpie

(Production Method) A. Components (1), (3), (4), (6) and (9) were mixed and mixed at 70 ° C.
Heat and stir. B. Mix components (2), (5), (7) and (8). C. The above B was added to the above A, mixed, and then cooled to obtain a pack.

Example 22 Cleaning Agent: A cleaning agent was prepared by the following formulation and the following production method. (Process) Amount (%) (1) Stearic acid 10.0 (2) Palmitic acid 8.0 (3) Myristic acid 12.0 (4) Lauric acid 4.0 (5) Oleyl alcohol 1.5 (6) Purified lanolin 1.0 (7) Perfume 0.1 (8) Preservative 0.2 (9) Glycerin 18.0 (10) Potassium hydroxide 6.0 (11) Astaxanthins ^{* 1} 0.0. 5 (12) Keratin hydrolyzate ^{* 2} 0.05 (13) Residual amount of purified water * 1 Produced in Reference Example 2. * 2 Seiwa Kasei

(Production Method) A. Components (9), (10) and (13) are mixed and heated to 70 ° C. B. Components (1)-(6), (8) and (11) are mixed and heated to 70 ° C. C. The above B was added to the above A, kept at 70 ° C for a while, cooled to 50 ° C after the saponification reaction was completed, and the components (7) and (1
2) was added and cooled to obtain a cleaning agent.

Example 23 Hair Tonic: A hair tonic was prepared according to the following formulation and the following production method. (Process) Amount (%) (1) Astaxanthin ^{* 1} 0.1 (2) Chamomile extract ^{* 2} 0.3 (3) Menthol 0.1 (4) Ethanol 40.0 (5) Perfume suitable Amount (6) Purified water Residual amount * 1 Produced in Reference Example 2. * 2 Made by Ichimaru Falcos

(Production Method) A. Components (1) and (3) to (5) are mixed and dissolved. B. Mix and dissolve components (2) and (6). C. A was added to B and mixed uniformly to obtain a hair tonic.

[0135]

EFFECTS OF THE INVENTION According to the present invention, the inherent performance of the medicinal agent can be fully exerted. For example, the composition of the present invention containing an active oxygen scavenger or an antioxidant as a medicinal agent has an excellent active oxygen scavenging action, and improves rough skin,
Since it has a stable and excellent effect in preventing skin aging,
It has an extremely high preventive effect against the generation of lipid peroxide, inflammation, blackening, aging, etc. due to the generation of active oxygen in the skin due to ultraviolet rays. On the other hand, the composition of the present invention containing a cell activating agent as a medicinal agent has an excellent cell activating action, so that it is effective in preventing skin aging, wounds, cracks, cracks, sores, hemorrhoids, improving burns, and promoting wound healing. Etc. are effective.

Further, the composition of the present invention containing an anti-inflammatory agent or a tyrosinase activity inhibitor as a medicinal agent has a stable and excellent anti-inflammatory and whitening effect, and therefore highly suppresses skin inflammation and pigmentation. It is effective in preventing and improving skin blackening due to sunburn, stains and freckles. Furthermore, the composition of the present invention containing a moisturizer as a medicinal agent is stable and has an excellent effect of improving rough skin, and therefore is effective in preventing and improving the occurrence of "dullness" of the skin. As described above, the composition of the present invention can sufficiently exhibit the intrinsic performance of a medicinal agent, and is extremely useful in beauty and medicine. that's all

─────────────────────────────────────────────────── ─── Continuation of the front page (51) Int.Cl. ⁶ Identification code Internal reference number FI Technical display area A61K 7/00 A61K 7/00 K J U 7/48 7/48 31/045 31/045 31/5 07 31/07 31/095 31/095 31/19 31/19 31/21 31/21 31/35 31/35 31/355 31/355 31/375 31/375 31/40 31/40 31/415 31 / 415 31/44 31/44 31/51 31/51 31/525 31/525 31/575 31/575 31/59 31/59 31/70 31/70 31/715 31/715 31/725 31/725 33/00 33/00 35/14 35/14 Z 35/28 35/28 35/50 35/50 35/64 35/64 35/74 35/74 Z 35/78 35/78 BC 35/84 35 / 84 A 38/00 45/06 ADA 38/44 AED 37/02 45/06 ADA 37/50 AED (72) Inventor Chiharu Kondo 48-18 Sakaemachi, Kita-ku, Tokyo Inside Kose Research Institute (72) Inventor Masami Senoo 48-18 Sakaemachi, Kita-ku, Tokyo Inside Kose Research Institute Co., Ltd. (72) Eiji Yamashita Kitaya Sancho, Tokushima City, Tokushima Prefecture 3-5-46-301

Claims (18)

[Claims] 1. A component selected from the following components (A) and (B) (A) astaxanthin (B) active oxygen scavenger, antioxidant, cell activator, anti-inflammatory agent, tyrosinase activity inhibitor and moisturizer. A composition comprising one or more medicinal agents. 2. The composition according to claim 1, wherein the medicinal agent is an active oxygen scavenger. 3. A plant extract containing a flavonoid such as SOD, mannitol, hydroquinone, bilirubin, cholesterol, tryptophan, histidine, quercetin, quercitrin, gallic acid, gallic acid derivatives, and Ginkgo biloba extract in the active oxygen scavenger. The composition according to claim 2, wherein the composition is selected from the group consisting of an extract, an extract of Gokahi, an extract of Yashajitsu, and an extract of Zikoppi. 4. The composition according to claim 1, wherein the medicinal agent is an antioxidant. 5. Antioxidants include vitamins A and derivatives thereof and salts thereof, vitamins B and derivatives thereof and salts thereof, vitamin C and derivatives thereof and salts thereof, vitamins D and salts thereof. Derivatives and salts thereof, vitamin E and derivatives thereof and salts thereof, glutathione and derivatives thereof and salts thereof, B
The composition according to claim 4, which is selected from HT and BHA. 6. The composition according to claim 1, wherein the medicinal agent is a cell activating agent. 7. A cell activating agent is a deoxyribonucleic acid and a salt thereof, an adenylic acid derivative such as adenosine triphosphate and adenosine monophosphate and a salt thereof, ribonucleic acid and a salt thereof, guanine, xanthine and a derivative thereof, and them. -Related substances such as salt of lactic acid; extracts derived from animals such as serum deproteinization extract, spleen extract, placenta extract, chicken cob extract, royal jelly; yeast extract, lactic acid bacterium extract, bifidobacteria extract, ganoderma lucidum Extracts derived from microorganisms such as extracts; carrot extracts, senburi extracts, rosemary extracts, oat extracts, garlic extracts, hinokitiol, plant-derived extracts such as cepharanthin; α- or γ-linolenic acid, Eicosapentaenoic acid and derivatives thereof, succinic acid and derivatives thereof and salts thereof,
7. The composition according to claim 6, which is selected from estradiol and derivatives thereof and salts thereof, α-hydroxy acids such as glycolic acid, lactic acid, malic acid, citric acid and salicylic acid, derivatives thereof and salts thereof. Stuff. 8. The composition according to claim 1, wherein the medicinal agent is an anti-inflammatory agent. 9. The anti-inflammatory agent is glycyrrhizic acid, glycyrrhetinic acid, mefenamic acid, phenylbutazone, indomethacin, ibuprofen, ketoprofen, allantoin, guaiazulene and their derivatives, and salts thereof, ε-aminocaproic acid, zinc oxide, diclofenac. The composition according to claim 8, which is selected from sodium, aloe extract, salvia extract, arnica extract, chamomile extract, birch extract, hypericum extract, eucalyptus extract and mukurodi extract. 10. The composition according to claim 1, wherein the drug is a tyrosinase activity inhibitor. 11. A tyrosinase activity inhibitor comprises cysteine and its derivatives, and salts thereof, Sempukuka extract, Caiketo extract, Sunpens extract, Sophoraceae extract, Toki extract, Ibukitalano extract, Clara extract, Hawthorn extract. Thing, white lily extract, hop extract,
The composition according to claim 10, which is selected from Neurose extract and Yokuinin extract. 12. The composition according to claim 1, wherein the medicinal agent is a moisturizing agent. 13. The composition according to claim 12, wherein the humectant is a mucopolysaccharide and / or a protein. 14. The composition according to claim 13, wherein the mucopolysaccharide is selected from hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin and keratan sulfate, and salts thereof. 15. The composition according to claim 13, wherein the protein is selected from collagen, elastin, keratin, derivatives thereof, and salts thereof. 16. The composition according to any one of claims 1 to 15, which is a skin external preparation. 17. A cosmetic product according to any one of claims 1 to 1.
The composition according to any one of item 5. 18. The composition according to any one of claims 1 to 15, which is a topical drug.